Headquartered in Malvern, PA Fiscal year ends December NYSE: ANVS annovisbio.com
Annovis Bio, Inc. (NYSE: ANVS) is a Phase 3 clinical-stage biotechnology company developing buntanetap (formerly posiphen), an investigational once-daily oral therapy for neurodegenerative diseases including Alzheimer's disease and Parkinson's disease. Buntanetap works by inhibiting the translation of multiple neurotoxic proteins — including APP, amyloid beta, tau, alpha-synuclein, and TDP-43 — through a specific RNA-targeting mechanism. The company's most advanced program is a pivotal Phase 3 trial in early Alzheimer's disease with 850 enrolled patients, designed to evaluate both symptomatic and disease-modifying effects. Annovis is also conducting an open-label extension study in Parkinson's disease across 26 U.S. clinical sites. The company is pre-revenue and funds its operations through equity offerings. Updated
Dementia is a major healthcare problem across the globe. It is estimated by medical professionals that someone develops some form of dementia every three seconds, and about 55-60 million people currently suffer…
Annovis Bio, Inc. (NYSE: ANVS) is a Phase 3 clinical-stage biotechnology company developing buntanetap (formerly posiphen), an investigational once-daily oral therapy for neurodegenerative diseases including Alzheimer's disease and Parkinson's disease.
The Wall Street consensus 12-month price target for ANVS is $10.50.
